Japanese Population Prostate Cancer and Benign Prostatic Hyperplasia in a Gene Polymorphism with Vitamin D Receptor Association of Updated Version
暂无分享,去创建一个
T. Habuchi | O. Ogawa | N. Tsuchiya | Tetsuro Kato | S. Satoh | N. Shimoda | A. Koizumi | Y. Wada | J. Chihara | R. Sasaki | T. Akao | Takehiro Suzuki
[1] K. Miyazono,et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. , 1999, Science.
[2] T. Stamey,et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.
[3] D. Hunter,et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[4] K. Burnstein,et al. Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation. , 1998, Endocrinology.
[5] G. Hitman,et al. Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians , 1997, Diabetologia.
[6] D. Morris,et al. The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). , 1997, British journal of urology.
[7] A. Hofman,et al. Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. , 1997, The Journal of clinical investigation.
[8] D. Kiel,et al. The BsmI Vitamin D Receptor Restriction Fragment Length Polymorphism (bb) Influences the Effect of Calcium Intake on Bone Mineral Density , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] N. Weigel,et al. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.
[10] J. Rastad,et al. Vitamin D receptor alleles b, a, and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1. , 1997, Biochemical and biophysical research communications.
[11] G. Coetzee,et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[12] G. Coetzee,et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.
[13] M. Becich,et al. The role of vitamin D in normal prostate growth and differentiation. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[14] J. Mohler,et al. Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.
[15] J. Eisman,et al. Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] H. Guess,et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. , 1995, The Journal of urology.
[17] T. Beaty,et al. Genetic susceptibility of benign prostatic hyperplasia. , 1994, The Journal of urology.
[18] G. Swanson,et al. Descriptive epidemiology of prostate cancer in metropolitan detroit , 1994, Cancer.
[19] T. Stamey,et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.
[20] J. Eisman,et al. Prediction of bone density from vitamin D receptor alleles , 1994, Nature.
[21] H. Akaza,et al. Comparison of various assay systems for prostate-specific antigen standardization. , 1992, Japanese journal of clinical oncology.
[22] J. Eisman,et al. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] M. Lucia,et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. , 1992, Cancer research.
[24] J. Shine,et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Haussler,et al. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. , 1987, Science.
[26] Tetsuro Kato,et al. [Histological study on hyperplasia of the prostate with special reference to histogenesis of nodule]. , 1967, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[27] Ames,et al. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. , 1997, The New England journal of medicine.
[28] N. Weigel,et al. 1 , 25-Dihydroxyvitamin D 3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G 1 * , 1997 .
[29] O. Yoshida,et al. The geography of prostate cancer and its treatment in Japan. , 1995, Cancer surveys.
[30] D. Peehl,et al. Actions Of Vitamin D, Analogs on Human Prostate Cancer Cell Lines: Comparison with , 1995 .
[31] H A Guess,et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia , 1990, The Prostate.
[32] B. Hulka,et al. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990, Anticancer research.